Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

NCT02088684 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: LEE011
DRUG: BYL719
DRUG: fulvestrant
DRUG: BKM120

Sponsor

Novartis Pharmaceuticals